|
2,5-Xylidine
|
DB02163 |
|
|
4,6-Dideoxy-4-{[4,5,6-Trihydroxy-3-(Hydroxymethyl)Cyclohex-2-En-1-Yl]Amino}-Alpha-D-Lyxo-Hexopyranosyl-(1->4)-Alpha-D-Threo-Hexopyranosyl-(1->6)-Alpha-L-Threo-Hexopyranose
|
DB03495 |
|
|
N-sulfo-flavin mononucleotide
|
DB02164 |
|
|
Hydroxy-Phenyl-Acetic Acid 8-Methyl-8-Aza-Bicyclo[3.2.1]Oct-3-Yl Ester
|
DB02161 |
|
|
lambda-bis(2,2'-bipyridine)imidazole osmium (II)
|
DB03492 |
|
|
5'-O-(N-Ethyl-Sulfamoyl)Adenosine
|
DB02162 |
|
|
7-Methylguanosine
|
DB03493 |
|
|
3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
|
DB03490 |
|
|
S-Butyryl-Cystein
|
DB02160 |
|
|
2'-Deoxyguanosine-5'-Diphosphate
|
DB03491 |
|
|
Glyceryl stearate SE
|
DB14149 |
|
|
Human albumin microspheres
|
DB14148 |
|
|
Zirconium chloride hydroxide
|
DB15479 |
|
|
Nepidermin
|
DB14145 |
|
|
Haemagglutinin-strain A(H1N1)
|
DB15476 |
|
|
Haemagglutinin-strain A(H3N2)
|
DB15475 |
|
|
p-Aminophenol
|
DB14144 |
|
|
Frangula purshiana bark
|
DB15478 |
|
|
Alloin
|
DB15477 |
|
|
Loxicodegol
|
DB14146 |
[Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain [L3263]. The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class [A33997, A34016]. This is also thought to be the reason behind the reduced frequency of CNS-mediated adverse effects, like sedation, seen with Loxicodegol. Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263]] |
